Navigation Links
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
Date:6/15/2009

QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic hyperplasia (BPH) with its lead endocrinology compound, cetrorelix pamoate, is scheduled to be completed at the end of this week. Therefore, data analysis and reporting will be brought forward from the scheduled fourth quarter into the third quarter of 2009, and will follow the disclosure of results from the first double-blind placebo controlled efficacy study (study 033). BPH is a benign enlargement of the prostate, affecting more than 20 million men in the U.S. alone.

"We are very pleased to have reached this stage of the Phase 3 development of cetrorelix in BPH and look forward to the data emerging in the next quarter. We are also pleased that the ongoing reviews of safety data from our Data and Safety Monitoring Committee have not shown any need for protocol or study procedure amendments to the studies," said Paul Blake M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris.

The safety study (041) titled, "Cetrorelix pamoate in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study", will assess an intermittent dosage regimen of cetrorelix pamoate as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. Patients receive cetrorelix pamoate by intra-muscular (IM) injection at Weeks 0 and 2, and are followed up to Week 26. The main endpoint is the incidence of possibly drug-related adverse events. More information on this trial may be obtained at www.clinicaltrials.gov under the reference number NCT00
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
3. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
4. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
5. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
6. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
7. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
8. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
9. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
10. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
11. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Tris Pharma, a specialty ... today announced that it has been selected as an ... Association,s 2014 Awards for Excellence competition in ... independent panel of judges from SCORE (Counselors to America,s ... will be honored at a gala event to be ...
(Date:8/27/2014)... 27, 2014 After the boom of ... the next beverage craze is going to be the ... formulators can use Stress Relief energy pattern which can ... making of a beverage, including minerals, herbs and liquids. ... channeling that power into rapid recovery and helping to ...
(Date:8/27/2014)... WriteResult, LLC – a premier provider of ... superiority when it comes to meeting the needs of ... of their most recent study closeout on-time and with ... digital writing platform to collect Patient Reported Outcomes electronically ... drew data from a number of assessments including the ...
(Date:8/26/2014)... ANGELES , Aug. 26, 2014  NeuroSigma, Inc., ... company established to develop bioelectronic technologies, today announced that ... with the U.S. Securities and Exchange Commission relating to ... The number of shares to be offered and the ... been determined. Jefferies LLC will act as ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... noses modeled after biological olfaction, the challenge has been ... requisite combinatorial complexity to detect odors in the real ... be manufactured with exact chemical precision and reproducibility. , ... open-access journal PLoS Biology, Joel White, Mary AtKisson, John ...
... Fla., Jan. 22 The Delaware Court of,Chancery today ... brought by a,stockholder of Cryo-Cell International Inc. (OTC Bulletin ... of stockholders held,on July 16, 2007. The court ordered ... a special stockholders meeting to be held on March ...
... Hospitals and healthcare,institutions are challenged to devise ... take place while maintaining Environment of Care,(EC) ... these challenges is,available for download at: ... "Infection Control in the Healthcare,Environment During Construction," ...
Cached Biology Technology:Special Stockholders Meeting to Elect Directors Set for March 4, 2008 2White Paper Details Infection Control Challenges Hospitals Must Address During Construction 2
(Date:8/27/2014)... the greatest risk to Europe based upon a proxy ... researchers using a ,big data, approach to scientific research. ... and Global Health ranked the top 100 pathogens affecting ... a system which, they believe, will help governments across ... of infectious diseases, including as a result of climate ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
(Date:8/27/2014)... basic research, a growing focus on translating discoveries ... have earned the Herbert Irving Comprehensive Cancer Center ... NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center ... The grant renews the center,s status as one ... New York City and one of only three ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... vast majority of patients who had a successful ... need mitral valve surgery three years after their ... of the left ventricle (commonly known as reverse ... the Cardiovascular Research Foundations (CRF) nineteenth annual Transcatheter ...
... D.C. October 24, 2007 - The U.S. Senate ... Appropriations Bill (S.1710), including a provision that directs the ... Access Policy by requiring rather than requesting participation by ... House Appropriations Bill, which contains a similar provision, in ...
... Germany-October 24, 2007-Harvard University,s Office of Technology Development ... jointly establish the BASF Advanced Research Initiative. ... and Applied Sciences (SEAS) the initiative will benefit ... throughout the University. Set up as a ...
Cached Biology News:New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3Mandate for public access to NIH-funded research poised to become law 2BASF and Harvard University announce extensive research collaboration 2